Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With... Key PointsQuestionWhat is the clinical activity and safety of combination therapy of niraparib plus pembrolizumab in patients with platinum-based chemotherapy–resistant ovarian carcinoma or those not eligible for retreatment with a platinum-based chemotherapy? FindingsSixty-two patients with ovarian carcinoma were enrolled in this open-label, single-arm phases 1 and 2 study. Among the 60 evaluable patients, 3 had complete responses, 8 had partial responses, and 28 had stable disease. MeaningCombination niraparib plus pembrolizumab therapy showed promising antitumor activity in patients with ovarian carcinoma, warranting further investigation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/american-medical-association/single-arm-phases-1-and-2-trial-of-niraparib-in-combination-with-kT3bqpEdpX
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2019.1048
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionWhat is the clinical activity and safety of combination therapy of niraparib plus pembrolizumab in patients with platinum-based chemotherapy–resistant ovarian carcinoma or those not eligible for retreatment with a platinum-based chemotherapy? FindingsSixty-two patients with ovarian carcinoma were enrolled in this open-label, single-arm phases 1 and 2 study. Among the 60 evaluable patients, 3 had complete responses, 8 had partial responses, and 28 had stable disease. MeaningCombination niraparib plus pembrolizumab therapy showed promising antitumor activity in patients with ovarian carcinoma, warranting further investigation.

Journal

JAMA OncologyAmerican Medical Association

Published: Aug 13, 2019

References